CBLL · Ceribell, Inc.
$24.20
-0.11 (-0.45%)
At close · Aug 21
Market Cap
$932.97M
Shares
38.38M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.20
Open$24.31
Day$23.80–24.33
52W close$10.92–24.89
Avg vol 30d426K
Short int2.0M · 5.3% float · 5.5d
Short vol32%
Last earningsAug 10, 2026
DataOct 2024–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
+24%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+43%
trailing
6-month return
+33%
trailing
YTD return
+10%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +16 funds added
Insider flow
Distributing
Net -$4.5M over 90 days · 100% sells
Short interest
Rising
5.26% of float · ▲ +9.2% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
122 holders — near 1-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
Gross margin
88%
expanding
EPS growth
+57%
Y/Y
Free cash flow
$-41.6M
Balance sheet
$20.7M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 10, 2026
Total revenue
· full year 2026
Initiated
$114M – $117M
prior FY $89.06M
midpoint +29.7% Y/Y
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Revenue
· full-year 2025
$87M – $89M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
+24%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +16 funds added
Insider flow
Distributing
Net -$4.5M over 90 days · 100% sells
Short interest
Rising
5.26% of float · ▲ +9.2% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
122 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $24 · 95%
Range high $25
vs 200-day avg +26%
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | -$9.82M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA loss non-GAAP | $9.8M | Q2 2026 | — |
|
|
|||
| EBITDA (Non-GAAP) non-GAAP | -$19.74M | the three months ended June 30, 2026 filing | — |
| Gross margin | 92% | Q2 2026 | — |
|
|
|||
| Total active accounts | 712 | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBLL
this stock
Ceribell, Inc.
|
$932.97M | +10.4% | +36.1% | — | 5.3% |
|
ABT
Abbott Laboratories
|
$198.81B | -6.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$126.37B | -6.3% | +11.2% | 34.1 | 2.2% |
|
MDT
Medtronic plc
|
$119.47B | -2.8% | +8.4% | 25.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -47.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBLL | +3.7% | +43.1% | +33.3% | +36.8% | +10.4% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +5.1% | +39.5% | +21.7% | +34.3% | -1.9% |
Key facts
CIK
1861107
CUSIP
15678C102
13F (30d)
114 filings
111 filers
Visit website
Investor relations